Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Abstract Background During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-05-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13014-020-01544-0 |
| _version_ | 1817989888044171264 |
|---|---|
| author | Rosario Mazzola Barbara Alicja Jereczek-Fossa Davide Franceschini Slavisa Tubin Andrea Riccardo Filippi Maria Tolia Andrea Lancia Giuseppe Minniti Stefanie Corradini Stefano Arcangeli Marta Scorsetti Filippo Alongi |
| author_facet | Rosario Mazzola Barbara Alicja Jereczek-Fossa Davide Franceschini Slavisa Tubin Andrea Riccardo Filippi Maria Tolia Andrea Lancia Giuseppe Minniti Stefanie Corradini Stefano Arcangeli Marta Scorsetti Filippo Alongi |
| author_sort | Rosario Mazzola |
| collection | DOAJ |
| description | Abstract Background During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer. Material and method Narrative Review regarding retrospective and prospective studies published between January 2009 to November 2019 with at least 20 patients analyzed. Results Concerning the combination between SBRT and Immunotherapy, the correct sequence of remains uncertain, and seems to be drug-dependent. The optimal patients’ selection is crucial to expect substantial benefits to SBRT/Immunotherapy combination and, among several factors. A potential field of interest is represented by the so-called oligoprogressed disease, in which SBRT could improve the long-term efficacy of the existing target therapy. Conclusions A low tumor burden seems to be the most relevant, thus making the oligometastatic disease represent the ideal setting for the use of combination therapies with immunological drugs. |
| first_indexed | 2024-04-14T00:52:52Z |
| format | Article |
| id | doaj.art-c0301203d9194c2bbd78bd76d429581b |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-04-14T00:52:52Z |
| publishDate | 2020-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-c0301203d9194c2bbd78bd76d429581b2022-12-22T02:21:44ZengBMCRadiation Oncology1748-717X2020-05-0115111310.1186/s13014-020-01544-0Oligometastasis and local ablation in the era of systemic targeted and immunotherapyRosario Mazzola0Barbara Alicja Jereczek-Fossa1Davide Franceschini2Slavisa Tubin3Andrea Riccardo Filippi4Maria Tolia5Andrea Lancia6Giuseppe Minniti7Stefanie Corradini8Stefano Arcangeli9Marta Scorsetti10Filippo Alongi11IRCCS, Advanced Radiation Oncology Department, Sacro Cuore Don Calabria HospitalDepartment of Radiation Oncology IEO, European Institute of Oncology IRCCSRadiotherapy and Radiosurgery Department, Humanitas Cancer CenterKABEG Klinikum Klagenfurt, Institute of Radiation OncologyRadiation Oncology, Fondazione IRCCS Policlinico San MatteoFaculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of LarissaRadiation Oncology, Fondazione IRCCS Policlinico San MatteoRadiation Oncology Unit, Department of Medicine, Surgery and Neuroscience, University of SienaDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, Policlinico S. Gerardo and University of Milan “Bicocca”Radiotherapy and Radiosurgery Department, Humanitas Cancer CenterIRCCS, Advanced Radiation Oncology Department, Sacro Cuore Don Calabria HospitalAbstract Background During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer. Material and method Narrative Review regarding retrospective and prospective studies published between January 2009 to November 2019 with at least 20 patients analyzed. Results Concerning the combination between SBRT and Immunotherapy, the correct sequence of remains uncertain, and seems to be drug-dependent. The optimal patients’ selection is crucial to expect substantial benefits to SBRT/Immunotherapy combination and, among several factors. A potential field of interest is represented by the so-called oligoprogressed disease, in which SBRT could improve the long-term efficacy of the existing target therapy. Conclusions A low tumor burden seems to be the most relevant, thus making the oligometastatic disease represent the ideal setting for the use of combination therapies with immunological drugs.http://link.springer.com/article/10.1186/s13014-020-01544-0OligometastasisImmunotherapyTarget therapyMetastases-directed therapy |
| spellingShingle | Rosario Mazzola Barbara Alicja Jereczek-Fossa Davide Franceschini Slavisa Tubin Andrea Riccardo Filippi Maria Tolia Andrea Lancia Giuseppe Minniti Stefanie Corradini Stefano Arcangeli Marta Scorsetti Filippo Alongi Oligometastasis and local ablation in the era of systemic targeted and immunotherapy Radiation Oncology Oligometastasis Immunotherapy Target therapy Metastases-directed therapy |
| title | Oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| title_full | Oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| title_fullStr | Oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| title_full_unstemmed | Oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| title_short | Oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| title_sort | oligometastasis and local ablation in the era of systemic targeted and immunotherapy |
| topic | Oligometastasis Immunotherapy Target therapy Metastases-directed therapy |
| url | http://link.springer.com/article/10.1186/s13014-020-01544-0 |
| work_keys_str_mv | AT rosariomazzola oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT barbaraalicjajereczekfossa oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT davidefranceschini oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT slavisatubin oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT andreariccardofilippi oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT mariatolia oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT andrealancia oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT giuseppeminniti oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT stefaniecorradini oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT stefanoarcangeli oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT martascorsetti oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy AT filippoalongi oligometastasisandlocalablationintheeraofsystemictargetedandimmunotherapy |